New hope for kids with rare muscle disease: Long-Term drug safety trial begins
NCT ID NCT06435312
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 3 times
Summary
This study looks at the long-term safety of a daily injection called zilucoplan in children with a rare muscle-weakening disease called generalized myasthenia gravis. It includes up to 8 children who have already completed a previous study. The goal is to see if the drug remains safe and tolerable over an additional 52 weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mg0015 20220
Seoul, South Korea
-
Mg0015 40144
Milan, Italy
-
Mg0015 40218
Warsaw, Poland
-
Mg0015 40735
Glasgow, United Kingdom
-
Mg0015 40736
London, United Kingdom
-
Mg0015 40774
Katowice, Poland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at debilitating muscle weakness
- New hope for myasthenia gravis: experimental drug CNP-106 enters human trials
- New hope for myasthenia gravis patients: experimental drug enters phase 2 trial
- New drug trial aims to ease muscle weakness in rare disease
- New shot could ease daily struggles for myasthenia gravis patients
- New study lets myasthenia gravis patients rate their own symptoms on a new drug